Factbox-Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are currently investing billions of dollars to significantly boost their presence within the US. This strategic surge in investment is occurring as these international pharmaceutical companies rush to secure their operations and supply chains. The primary driver behind this rapid expansion is the looming threat of tariffs, which has prompted firms to prioritize domestic growth to avoid potential financial disruptions and ensure continued market access within the United States healthcare sector.